175463-14-6

ChEBI: A 1,4-dihydro-1,8-naphthyridine with a carboxy group at the 3-position, an oxo sustituent at the 4-position, a fluoro substituent at the 5-position and a substituted pyrrolin-1-yl group at the 7-position.

LG Life Sciences (formerly LG Chemical) has developed gemifloxacin (SB-265805, LB-20304a), a fluoronaphthyridone active against both Gram-positive and Gram-negative bacteria, including methicillin-resistant staphylococci, as a treatment for bacterial infection. By December 2002, the drug had been approved in Korea.

Acyl Glucuronide - Gemifloxacin is a derivative of Gemifloxacin (G336000); a third generation fluorinated quinolone antibacterial.

The broad antibacterial spectrum embraces most Gram-positive cocci (including high potency against Str. pneumoniae) and Gram-negative bacilli. It possesses a high affinity for pneumococcal topoisomerase IV. Activity against Gram-negative respiratory tract pathogens such as H. influenzae, Mor. catarrhalis, Ch. pneumoniae, L. pneumophila and Mycoplasma pneumonia is good. It is relatively inactive against Ps. aeruginosa and Enterococcus spp. Activity against Enterobacteriaceae is similar to that of moxifloxacin but it is less potent against anaerobes. Gemifloxacin is inactive against M. tuberculosis. Activity against Nocardia asteroides (MIC 0.5–1 mg/L) is better than that of other quinolones other than the investigational compound nemonoxacin .
Multistep resistance studies suggest that it is less likely than other quinolones to select for quinolone-resistant Str. pneumoniae strains. Because it inhibits both DNA gyrase and DNA topoisomerase IV enzyme systems at therapeutically relevant drug levels in Str. pneumoniae, single mutations in parC or gyrA result in only a small increase in the MIC. In Str. pneumoniae gyrA mutations arise at a lower rate (1.6 × 10?11) than mutations in parC. It seems to be unaffected clinically by quinolone efflux mechanisms in Str. pneumoniae. Low rates of resistance selection have also been reported in H. influenzae.

A fluoronaphthyridone derivative with a dual substituted pyrrolidine moiety at the C-7 position. It is formulated as the mesylate.

absorption and distribution
In oral escalating dose studies (single doses of 20–800 mg), Cmax ranged from 0.12 to 4.33 mg/L after an average of 1 h. Antacids significantly reduce the systemic availability and protein binding is relatively high. Excellent concentrations are achieved in serum as well as various tissues such as bronchial mucosa, epithelial lining fluid and alveolar macrophages. Absolute bioavailability of the 320 mg oral tablet is around 71%. Pharmacokinetics are not significantly altered when administered with a high fat meal.
Metabolism and excretion
The apparent elimination half-life ranges from 6 to 9 h, and 26–40% of administered doses are eliminated in urine. It is metabolized to a limited extent in the liver. Cytochrome P₄₅₀ enzymes do not play an important role in metabolism, and the metabolic activity of these enzymes is unaffected. Around 65% of the parent compound and its metabolites are eliminated in the feces and the remainder in the urine. The mean renal clearance after repeated doses of 320 mg is about 11.6 L/h, indicating active renal secretion. The mean apparent elimination half-life at steady state following administration of 320 mg to healthy subjects was approximately 7 h. No dosage adjustment is recommended in patients with mild, moderate or severe hepatic impairment. Clearance is reduced and plasma elimination is prolonged in patients with renal insufficiency, leading to an average increase in AUC values of c. 70%. Hemodialysis removes approximately 20–30% of an oral dose from plasma.

Community-acquired pneumonia in adults
Acute exacerbations of chronic bronchitis in adults

The most commonly reported side effects are diarrhea (3.6%), rash (2.8%) and nausea (2.7%). No evidence has emerged of a clinically significant prolongation in QTc interval. The phototoxicity potential is low and similar to that seen with ciprofloxacin. The overall incidence of drugrelated rash is 2.8%. The rash is most commonly mild, macropapular (occasionally urticarial), predominantly selflimiting, and mainly occurs in women under 40 years and in postmenopausal women on hormone replacement therapy after ≥10 days.

Oral gemifloxacin was approved by the FDA in April 2003. Two key intermediates, 3-aminomethyl-4-methoxyiminopyrrolidine (105) and 7- chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine- 3-carboxylic acid (108) were involved in the synthesis of gemifloxacin (XII). Michael addition of glycine ethyl ester hydrochloride (98) to acrylonitrile (99) in the presence of KOH furnished cyanoester 100 in 48% yield. Protection of the amino group and Dieckmann cyclization were accomplished in a one-pot process to furnish 4-cyano-1-(N-tbutoxycarbonyl)- pyrrolidine-3-one (101) in almost quantitative yield. The conversion of ketone 101 to alcohol 102 was achieved via three reaction sequences in a one-pot process in 83% yield. The hydroxy group was oxidized to ketone 103 with pyridine-sulfur trioxide complex in DMSO. Treatment of ketone 103 with methoxyamine in the presence of NaHCO3 provided methyloxime 104 in 88% yield.
Deprotection of the Boc groups in 104 by TFA afforded pyrrolidine 105 in 84% yield. Quinolone acid 108 was employed in the synthesis of ciprofloxacin and can be readily prepared according to literature methods. A four step sequence/one-pot process is depicted in Scheme 12. Nicotinoyl acetate 106 was converted to enaminoester 107 by reaction with ethyl orthoformate and acetic anhydride, followed by reaction with the cyclopropyl amine. 1,8-Naphthyridine 108 was obtained through baseassisted cyclization, followed by acid hydrolysis of the ester function via a one-pot process in 52% overall yield. The coupling reaction of quinolone 108 with pyrrolidine 105 was carried out in CH3CN-H2O in the presence of benzaldehyde and triethylamine. The benzaldehyde served as an important reagent to protect the primary amine selectively and therefore the desired gemifloxacin derivative 109 was obtained in high yield and purity, otherwise a 10% by-product was observed. The deprotection and salt formation reactions were carried out in one step by treatment of 109 with methanesulfonic acid at 40-45oC in water. The gemifloxacin mesylate (XII) was collected by filtration upon cooling in 95% yield.